Niki BiosolutionsNIKI
13F holders, Q4 2024 (December 31)4holders +2
1new positions
0sold out
$2.80avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Niki Biosolutions Inc. (NIKI) in their 13F filings, up 2 from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were Geode Capital Management, LLC ($107K), Morgan Stanley ($25K) and UBS Group AG ($594).
- Company
- Niki Biosolutions Inc.
- Filed as
- APTORUM GROUP LIMITED (Q4 2024)
- CUSIP
- G6096M122
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $594 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 212 shares bought and 8,215 shares sold, net −8,003 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Geode Capital Management, LLC | 0.00% | Reduce -3.2% | 38,389 | $107K |
| Morgan Stanley | 0.00% | Reduce -43.5% | 9,018 | $25K |
| UBS Group AG | 0.00% | New | 212 | $594 |
| SBI Securities Co., Ltd. | 0.00% | — | 135 | $378 |
"% of holder's portfolio" is NIKI's weight in each manager's 13F, not the share of Niki Biosolutions Inc. the manager owns.